Core Insights - The management of the company acknowledges significant changes in the pharmaceutical industry's operating environment and continues to work on improving the company's performance despite ongoing losses in its main business [1] - The company has completed Phase IIa clinical trials for its new drug, R- Ketorolac sustained-release patch, but there is uncertainty regarding the need for Phase IIb trials [1] - The company’s subsidiary, Xingya Pharmaceutical, has been sold for 175 million yuan, with the first payment of 30 million yuan already received, and the final payment expected by June 25 [1] - The company reported a decline in revenue for Q1 2025 due to weak market demand, intensified industry competition, and compressed pricing for generic drugs [1] Company Strategy - To improve operational conditions, the management plans to actively adjust the business structure, enhance promotion of high-margin products, and focus on building a strong VIP customer base [2] - The company aims to explore new uses for existing drugs to address the lack of new products in its pipeline [2] - The company is committed to launching CMO/CDMO projects, expanding into international markets, and seeking opportunities for industry consolidation to strengthen its core competitiveness [2]

证券代码：002370 证券简称：亚太药业 您好，感谢您对公司的关注！2025 年第一季度营收 下降主要系市场需求疲软、行业竞争加剧，仿制药行业 受国家集中带量采购政策等影响，药品价格空间被压缩， 导致企业营收承压所致。 3、公司 2025 年第一季度营收下降很多，是啥原因 呢？贵公司有没有考虑过如何扭转主营业绩？ 您好，感谢您对公司的关注！2025 年第一季度营收 下降主要系市场需求疲软、行业竞争加剧，仿制药行业 受国家集中带量采购政策等影响，药品价格空间被压缩， 导致企业营收承压所致。为改善公司经营状况，公司管 理层将尽全力做好经营工作，积极调结构，加大高毛产 品和临床品种招商推广力度；集优势，打造优质的 VIP 客户进行商业优势整合、渠道归拢，充分发挥大型商业 的区域优势；挖潜力，积极探索老药新做，以补充亚太 后继新品乏力的局面；引项目，全力做好 CMO/CDMO 项目 的落地，开拓国际市场，培育新的利润增长点；合理安 排和使用资金，提高资金使用效率，增加资金收益；积 极利用资本市场的有利平台，寻求产业整合的良好机遇， 以增强公司核心竞争力。 浙江亚太药业股份有限公司 投资者关系活动记录表 编号：202 ...